Shots:
- The EC has granted centralized marketing authorization to Zandoriah, a biosimilar version of Forsteo (teriparatide) for the treatment of osteoporosis in adults, across all 30 EEA states
- Zandoriah has demonstrated biosimilarity in line with EMA guidelines, with comprehensive comparability studies confirming similar quality, safety, and efficacy to the reference product
- Teriparatide is a synthetic form of parathyroid hormone that stimulates new bone formation by activating osteoblasts, while also increasing calcium absorption and reducing calcium loss through urine
Ref: CinnaGen | Image: CinnaGen | Press Release
Related News: GlycoNex Reports the P-III Trial Data on SPD8 (Biosimilar, Denosumab)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
